Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686097 | 1.00 | KDM4E (0.32) | KDM4E | |
| Hydrochloric Acid SCHEMBL29106338 | 0.99 | KDM4E (0.31) | KDM4E | |
| Hydrochloric Acid SCHEMBL29686221 | 0.99 | KDM4E (0.31) | KDM4E | |
| SCHEMBL29650940 | 0.88 | KDM4E (0.35) | KDM4E | |
| SCHEMBL24468603 | 0.88 | KDM4E (0.35) | KDM4E | |
| SCHEMBL29236344 | 0.81 | KDM4E (0.36) | KDM4E | |
| SCHEMBL24547734 | 0.80 | SMN1; SMN2 (0.45) | KDM4E | |
| SCHEMBL27267989 | 0.80 | CNR1 (0.42) | — | |
| SCHEMBL24547768 | 0.78 | NCF1 (0.36) | — | |
| SCHEMBL24547740 | 0.78 | RAB9A (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288435-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | Amgen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117062816-A | Tricyclic-amide-bicyclic PRMT5 inhibitors | 美国安进公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | KDM4E 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.